OBJECTIVE: To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. METHODS:Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebo-controlled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. RESULTS: There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. CONCLUSION:Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.
RCT Entities:
OBJECTIVE: To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. METHODS:Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebo-controlled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovineCII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. RESULTS: There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovineCIIpatients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. CONCLUSION: Oral solubilized bovineCII, added to existing therapy, did not improve disease activity in patients with RA.
Authors: Arno Hänninen; Nathan R Martinez; Gayle M Davey; William R Heath; Leonard C Harrison Journal: J Clin Invest Date: 2002-01 Impact factor: 14.808
Authors: Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst Journal: Arthritis Rheum Date: 2008-06
Authors: Leonard C Harrison; John M Wentworth; Yuxia Zhang; Esther Bandala-Sanchez; Ralph M Böhmer; Alana M Neale; Natalie L Stone; Gaetano Naselli; Julian J Bosco; Priscilla Auyeung; Maryam Rashidi; Petra Augstein; Grant Morahan Journal: Curr Diab Rep Date: 2013-10 Impact factor: 4.810
Authors: Nathan R Martinez; Petra Augstein; Antonis K Moustakas; George K Papadopoulos; Silvia Gregori; Luciano Adorini; David C Jackson; Leonard C Harrison Journal: J Clin Invest Date: 2003-05 Impact factor: 14.808